nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2008 | NON-THEMATIC REVIEW

Osteopontin: regulation in tumor metastasis

verfasst von: Philip Y. Wai, Paul C. Kuo

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Osteopontin is a secreted phosphoprotein that has been implicated as an important mediator of tumor metastasis and has been investigated for use as a biomarker for advanced disease and as a potential therapeutic target in the regulation of cancer metastasis. The OPN DNA sequence is highly conserved and the protein contains several important functional domains including α_vβ integrin and CD44 binding sites. High levels of OPN expression correlate with tumor invasion, progression or metastasis in multiple cancer. Studies demonstrate that osteopontin mediates the molecular mechanisms which determine metastatic spread, such as prevention of apoptosis, extracellular matrix proteolysis and remodeling, cell migration, evasion of host-immune cells and neovascularization. Transcriptional regulation of OPN is complex and involves multiple pathways, including AP-1, Myc, v-Src, Runx/CBF, TGF-B/BMPs/Smad/Hox, and Wnt/ß–catenin/APC/GSK–3ß/Tcf-4. The current state of knowledge of OPN biology suggests that it is an attractive target for therapeutic modulation of metastatic disease.

Senger, D. R., Wirth, D. F., & Hynes, R. O. (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell, 16(4), 885–893.PubMed

Fisher, L. W., Hawkins, G. R., Tuross, N., & Termine, J. D, (1987). Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. Journal of Biological Chemistry, 262(20), 9702–9708.PubMed

Kiefer, M. C., Bauer, D. M., & Barr, P. J. (1989). The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Research, 17(8), 3306.PubMed

Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W., et al. (1990). cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics, 7(4), 491–502.PubMed

Wrana, J. L., Zhang, Q., & Sodek, J. (1989). Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-I, osteopontin). Nucleic Acids Research, 17(23), 10119–10123.PubMed

Smith, J. H., & Denhardt, D. T. (1987). Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. Journal of Cellular Biochemistry, 34(1), 13–22.PubMed

Craig, A. M., Nemir, M., Mukherjee, B. B., Chambers, A. F., & Denhardt, D. T. (1988). Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochemical and Biophysical Research Communications, 157(1), 166–173.PubMed

Shiraga, H., Min, W., VanDusen, W. J., Clayman, M. D., Miner, D., Terrell, C. H., et al. (1992). Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proceedings of the National Academy of Sciences of the United States of America, 89(1), 426–430.PubMed

Patarca, R., Freeman, G. J., Singh, R. P., Wei, F. Y., Durfee, T., Blattner, F., et al. (1989). Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. Journal of Experimental Medicine, 170(1), 145–161.PubMed

10.

Craig, A. M., & Denhardt, D. T. (1991). The murine gene encoding secreted phosphoprotein 1 (osteopontin): Promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163–171.PubMed

11.

Denhardt, D. T., & Guo, X. (1993). Osteopontin: A protein with diverse functions. FASEB Journal, 7(15), 1475–1482.PubMed

12.

Senger, D. R., Perruzzi, C. A., Papadopoulos-Sergiou, A., & Van de Water, L. (1994). Adhesive properties of osteopontin: Regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Molecular Biology of the Cell, 5(5), 565–574.PubMed

13.

Attur, M. G., Dave, M. N., Stuchin, S., Kowalski, A. J., Steiner, G., Abramson, S. B., et al. (2001). Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis and Rheumatism, 44(3), 578–584.PubMed

14.

Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079–1086.

15.

Johnson, R. J., Gordon, K. L., Giachelli, C., Kurth, T., Skelton, M. M., & Cowley, A. W. (2000). Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS rat. Journal de L’hypertension, 18(10), 1497–1505.

16.

Noble, B. S., & Reeve, J. (2000). Osteocyte function, osteocyte death and bone fracture resistance. Molecular and Cellular Endocrinology, 159(1–2), 7–13.PubMed

17.

Scott, J. A., Weir, M. L., Wilson, S. M., Xuan, J. W., Chambers, A. F., & McCormack, D. G. (1998). Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. American Journal of Physiology, 275(6), H2258–H2265.PubMed

18.

Thomas, S. E., Lombard, I. D., Giachelli, C., Bohle, A., & Johnson, R. J. (1998). Osteopontin expression, tubulointerstitial disease, and essential hypertension. American Journal of Hypertension, 11(8), 954–961.PubMed

19.

Rollo, E. E., Laskin, D. L., & Denhardt, D. T. (1996). Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. Journal of Leukocyte Biology, 60(3), 397–404.PubMed

20.

Singh, K., Balligand, J. L., Fischer, T. A., Smith, T. W., & Kelly, R. A. (1995). Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. Journal of Biological Chemistry, 270(47), 28471–28478.PubMed

21.

Feng, B., Rollo, E. E., & Denhardt, D. T. (1995). Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clinical & Experimental Metastasis, 13(6), 453–462.

22.

Denhardt, D. T., Lopez, C. A., Rollo, E. E., Hwang, S. M., An, X. R., & Walther, S. E. (1995). Osteopontin-induced modifications of cellular functions. Annals of the New York Academy of Sciences, 760, 127–142.PubMed

23.

Hwang, S. M., Wilson, P. D., Laskin, J. D., & Denhardt, D. T. (1994). Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. Journal of Cellular Physiology, 160(1), 61–68.PubMed

24.

Hwang, S. M., Lopez, C. A., Heck, D. E., Gardner, C. R., Laskin, D. L., Laskin, J. D., et al. (1994). Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. Journal of Biological Chemistry, 269(1), 711–715.PubMed

25.

Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S., & Yamamoto, S. (1994). Cloning and characterization of the human osteopontin gene and its promoter. Biochemical Journal, 303(1), 255–262.PubMed

26.

Denhardt, D. T., & Noda, M. (1998). Osteopontin expression and function: role in bone remodeling. Journal of Cell Biology, 30–31, 92–102.

27.

O’Regan, A., & Berman, J. S. (2000). Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. International Journal of Experimental Pathology, 81(6), 373–390.PubMed

28.

Weber, G. F. (2001). The metastasis gene osteopontin: a candidate target for cancer therapy. Biochimica et Biophysica Acta, 1552(2), 61–85.PubMed

29.

Fedarko, N. S., Jain, A., Karadag, A., & Fisher, L. W. (2004). Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB Journal, 18(6), 734–736.PubMed

30.

Fisher, L. W., Jain, A., Tayback, M., & Fedarko, N. S. (2004). Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clinical Cancer Research, 10(24), 8501–8511.PubMed

31.

Senger, D. R., Perruzzi, C. A., Gracey, C. F., Papadopoulos, A., & Tenen, D. G. (1988). Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Research, 48(20), 5770–5774.PubMed

32.

Senger, D. R., Perruzzi, C. A., Papadopoulos, A., & Tenen, D. G. (1989). Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochimica et Biophysica Acta, 996(1–2), 43–48.PubMed

33.

Bautista, D. S., Densted, T. J., Chambers, A. F., & Harris, J. F. (1996). Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. Journal of Cellular Biochemistry, 61(3), 402–409.PubMed

34.

Patarca, R., Saavedra, R. A., & Cantor, H. (1993). Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Critical Reviews in Immunology, 13(3–4), 225–246.PubMed

35.

Behrend, E. I., Chambers, A. F., Wilson, S. M., & Denhardt, D. T. (1993). Comparative analysis of two alternative first exons reported for the mouse osteopontin gene. Journal of Biological Chemistry, 268(15), 11172–11175.PubMed

36.

Yamamoto, S., Hijiya, N., Setoguchi, M., Matsuura, K., Ishida, T., Higuchi, Y., et al. (1995). Structure of the osteopontin gene and its promoter. Annals of the New York Academy of Sciences, 760, 44–58.PubMed

37.

Franzen, A., & Heinegard, D. (1985). Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochemical Journal, 232(3), 715–724.PubMed

38.

Oldberg, A., Franzen, A., & Heinegard, D. (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg–Gly–Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America, 83(23), 8819–8823.PubMed

39.

Saitoh, Y., Kuratsu, J., Takeshima, H., Yamamoto, S., & Ushio, Y. (1995). Expression of osteopontin in human glioma. Its correlation with the malignancy. Laboratory Investigation, 72(1), 55–63.PubMed

40.

Senger, D. R., Asch, B. B., Smith, B. D., Perruzzi, C. A., & Dvorak, H. F. (1983). A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature, 302(5910), 714–715.PubMed

41.

Senger, D. R., & Perruzzi, C. A. (1996). Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochimica et Biophysica Acta, 1314(1–2), 13–24.PubMed

42.

Senger, D. R., & Perruzzi, C. A. (1985). Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Research, 45(11), 5818–5823.PubMed

43.

Ashkar, S., Weber, G. F., Panoutsakopoulou, V., Sanchirico, M. E., Jansson, M., Zawaideh, S., et al. (2000). Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science, 287(5454), 860–864.PubMed

44.

Helluin, O., Chan, C., Vilaire, G., Mousa, S., DeGrado, W. F., & Bennett, J. S. (2000). The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. Journal of Biological Chemistry, 275(24), 18337–18343.PubMed

45.

Giancotti, F. G., & Ruoslahti, E. (1999). Integrin signaling. Science, 285(5430), 1028–1032.PubMed

46.

Liaw, L., Almeida, M., Hart, C. E., Schwartz, S. M., & Giachelli, C. M. (1994). Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circulation Research, 74(2), 214–224.PubMed

47.

Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., & Giachelli, C. M. (1995). Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg–Gly–Asp-dependent endothelial migration in vitro. Circulation Research, 77(4), 665–672.PubMed

48.

Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., et al. (1995). The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. Journal of Clinical Investigation, 95(2), 713–724.PubMed

49.

Yue, T. L., McKenna, P. J., Ohlstein, E. H., Farach-Carson, M. C., Butler, W. T., Johanson, K., et al. (1994). Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Experimental Cell Research, 214(2), 459–464.PubMed

50.

Hu, D. D., Lin, E. C., Kovach, N. L., Hoyer, J. R., & Smith, J. W. (1995). A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. Journal of Biological Chemistry, 270(44), 26232–26238.PubMed

51.

Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., et al. (1996). Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. Journal of Biological Chemistry, 271(45), 28485–28491.PubMed

52.

Bayless, K. J., Meininger, G. A., Scholtz, J. M., & Davis, G. E. (1998). Osteopontin is a ligand for the alpha4beta1 integrin. Journal of Cell Science, 111(9), 1165–1174.PubMed

53.

Denda, S., Reichardt, L. F., & Muller, U. (1998). Identification of osteopontin as a novel ligand for the integrin alpha8 beta1 and potential roles for this integrin-ligand interaction in kidney morphogenesis. Molecular Biology of the Cell, 9(6), 1425–1435.PubMed

54.

Barry, S. T., Ludbrook, S. B., Murrison, E., & Horgan, C. M. (2000). A regulated interaction between alpha5beta1 integrin and osteopontin. Biochemical and Biophysical Research Communications, 267(3), 764–769.PubMed

55.

Gerber, D. J., Pereira, P., Huang, S. Y., Pelletier, C., & Tonegawa, S. (1996). Expression of alpha v and beta 3 integrin chains on murine lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 93(25), 14698–14703.PubMed

56.

Reinholt, F. P., Hultenby, K., Oldberg, A., & Heinegard, D. (1990). Osteopontin–a possible anchor of osteoclasts to bone. Proceedings of the National Academy of Sciences of the United States of America, 87(12), 4473–4475.PubMed

57.

Singh, R. P., Patarca, R., Schwartz, J., Singh, P., & Cantor, H. (1990). Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. Journal of Experimental Medicine, 171(6), 1931–1942.PubMed

58.

Bennett, J. S., Chan, C., Vilaire, G., Mousa, S. A., & DeGrado, W. F. (1997). Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin. Journal of Biological Chemistry, 272(13), 8137–8140.PubMed

59.

Denhardt, D. T., Noda, M., O, , Regan, A. W., Pavlin, D., & Berman, J. S. (2001). Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. Journal of Clinical Investigation, 107(9), 1055–1061.PubMed

60.

Smith, L. L., & Giachelli, C. M. (1998). Structural requirements for alpha 9 beta 1-mediated adhesion and migration to thrombin-cleaved osteopontin. Experimental Cell Research, 242(1), 351–60.PubMed

61.

Yasuyuki, Y., Matsuura, N., Sasaki, T., Murakami, I., Schneider, H., Higashiyama, S., et al. (1999). The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. Journal of Biological Chemistry, 274(51), 36328–36334.

62.

Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., et al. (2003). Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochemical and Biophysical Research Communications, 310(1), 153–157.PubMed

63.

Liapis, H., Flath, A., & Kitazawa, S. (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagnostic Molecular Pathology, 5(2), 127–135.PubMed

64.

Angelucci, A., Festuccia, C., D’Andrea, G., Teti, A., & Bologna, M. (2002). Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators. Biological Chemistry, 383(1), 229–234.PubMed

65.

Furger, K. A., Allan, A. L., Wilson, S. M., Hota, C., Vantyghem, S. A., Postenka, C. O., et al. (2003). Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Molecular Cancer Research, 1(11), 810–819.PubMed

66.

Senger, D. R., Ledbetter, S. R., Claffey, K. P., Papadopoulos-Sergiou, A., Peruzzi, C. A., & Detmar, M. (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. American Journal of Pathology, 149(1), 293–305.PubMed

67.

Scatena, M., Almeida, M., Chaisson, M. L., Fausto, N., Nicosia, R. F., & Giachelli, C. M. (1998). NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. Journal of Cell Biology, 141(4), 1083–1093.PubMed

68.

Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., et al. (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79(7), 1157–1164.PubMed

69.

Arap, W., Pasqualini, R., & Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279(5349), 377–380.PubMed

70.

Bayless, K. J., Salazar, R., & Davis, G. E. (2000). RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. American Journal of Pathology, 56(5), 1673–1683.

71.

Engleman, V. W., Nickols, G. A., Ross, F. P., Horton, M. A., Griggs, D. W., Settle, S. L., et al. (1997). A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation, 99(9), 2284–2292.PubMed

72.

Rabinowich, H., Lin, W. C., Amoscato, A., Herberman, R. B., & Whiteside, T. L. (1995). Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. Journal of Immunology, 154(3), 1124–1135.

73.

Goodison, S., Urquidi, V., & Tarin, D. (1999). CD44 cell adhesion molecules. Molecular Pathology, 52(4), 189–196.PubMed

74.

Weber, G. F., Ashkar, S., Glimcher, M. J., & Cantor, H. (1996). Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science, 271(5248), 509–512.PubMed

75.

Katagiri, Y. U., Sleeman, J., Fujii, H., Herrlich, P., Hotta, H., Tanaka, K., et al. (1999). CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine–glycine–aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Research, 59(1), 219–226.PubMed

76.

Rudzki, Z., & Jothy, S. (1997). CD44 and the adhesion of neoplastic cells. Molecular Pathology, 50(2), 7–71.

77.

Ponta, H., Sherman, L., & Herrlich, P. A. (2003). CD44: From adhesion molecules to signaling regulators. Nature Reviews, Molecular Cell Biology, 4(1), 33–45.

78.

Takahashi, K., Takahashi, F., Hirama, M., Tanabe, K. K., & Fukuchi, Y. (2003). Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer, 41(2), 145–153.PubMed

79.

Asosingh, K., Gunthert, U., Bakkus, M. H., De Raeve, H., Goes, E., Van Riet, I., et al. (2000). In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Research, 60(11), 3096–3104.PubMed

80.

Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., et al. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65(1), 13–24.PubMed

81.

Rudy, W., Hofmann, M., Schwartz-Albiez, R., Zoller, M., Heider, K. H., Ponta, H., et al. (1993). The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Research, 53(6), 1262–1268.PubMed

82.

Gao, C., Guo, H., Downey, L., Marroquin, C., Wei, J., & Kuo, P. C. (2003). Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis, 24(12), 1871–1878.PubMed

83.

Lin, Y. H., Huang, C. J., Chao, J. R., Chen, S. T., Lee, S. F., Yen, J. J., et al. (2000). Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte–macrophage colony-stimulating factor. Molecular and Cellular Biology, 20(8), 2734–2742.PubMed

84.

Zohar, R., Cheifetz, S., McCulloch, C. A., & Sodek, J. (1998). Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. European Journal of Oral Sciences, 106(1), 401–407.PubMed

85.

Zohar, R., Suzuki, N., Suzuki, K., Arora, P., Glogauer, M., McCulloch, C. A., et al. (2000). Intracellular osteopontin is an integral component of the CD44–ERM complex involved in cell migration. Journal of Cellular Physiology, 184(1), 118–130.PubMed

86.

Sodek, J., Ganss, B., & McKee, M. D. (2000). Osteopontin. Critical Reviews in Oral Biology and Medicine, 11(3), 279–303.PubMed

87.

Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, K., Perruzzi, C. A., et al. (1994). Osteopontin expression and distribution in human carcinomas. American Journal of Pathology, 145(3), 610–623.PubMed

88.

Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95–100.PubMed

89.

Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., et al. (1995). Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Laboratory Investigation, 72(1), 64–69.PubMed

90.

Singhal, H., Bautista, D. S., Tonkin, K. S., O, , Malley, F. P., Tuck, A. B., Chambers, A. F., et al. (1997). Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research, 3(4), 605–611.PubMed

91.

Tuck, A. B., O, , Malley, F. P., Singhal, H., Harris, J. F., Tonkin, K. S., Kerkvliet, N., et al. (1998). Osteopontin expression in a group of lymph node negative breast cancer patients. International Journal of Cancer, 79(5), 502–508.

92.

Casson, A. G., Wilson, S. M., McCart, J. A., O’Malley, F. P., Ozcelik, H., Tsao, M. S., et al. (1997). Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. International Journal of Cancer, 72(5), 739–745.

93.

Gotoh, M., Sakamoto, M., Kanetaka, K., Chuuma, M., & Hirohashi, S. (2002). Overexpression of osteopontin in hepatocellular carcinoma. Pathology International, 52(1), 19–24.PubMed

94.

Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research, 7(12), 4060–4066.PubMed

95.

Tuck, A. B., O, , Malley, F. P., Singhal, H., Tonkin, K. S., Harris, J. F., Bautista, D., et al. (1997). Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Archives of Pathology and Laboratory Medicine, 121(6), 578–584.PubMed

96.

Tuck, A. B., Arsenault, D. M., O, , Malley, F. P., Hota, C., Ling, M. C., Wilson, S. M., et al. (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18(29), 4237–4246.PubMed

97.

Ue, T., Yokozaki, H., Kitadai, Y., Yamamoto, S., Yasui, W., Ishikawa, T., et al. (1998). Co-expression of osteopontin and CD44v9 in gastric cancer. International Journal of Cancer, 79(2), 127–132.

98.

Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., et al. (1999). Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 160(4), 1269–1273.PubMed

99.

Chambers, A. F., Wilson, S. M., Kerkvliet, N., O, , Malley, F. P., Harris, J. F., & Casson, A. G. (1996). Osteopontin expression in lung cancer. Lung Cancer, 15(3), 311–323.PubMed

100.

Thalmann, G. N., Sikes, R. A., Devoll, R. E., Kiefer, J. A., Markwalder, R., Klima, I., et al. (1999). Osteopontin: Possible role in prostate cancer progression. Clinical Cancer Research, 5(8), 2271–2277.PubMed

101.

Pan, H. W., Ou, Y. H., Peng, S. Y., Liu, S. H., Lai, P. L., Lee, P. H., et al. (2003). Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 98(1), 119–127.PubMed

102.

Agrawal, D., Chen, T., Irby, R., Quackenbush, J., Chambers, A. F., Szabo, M., et al. (2002). Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute, 94(7), 513–521.PubMed

103.

Yeatman, T. J., & Chambers, A. F. (2003). Osteopontin and colon cancer progression. Clinical & Experimental Metastasis, 20(1), 85–90.

104.

Rudland, P. S., Platt-Higgins, A., El-Tanani, M., De Silva Rudland, S., Barraclough, R., Winstanley, J. H., et al. (2002). Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research, 62(12), 3417–3427.PubMed

105.

Wu, C. Y., Wu, M. S., Chiang, E. P., Wu, C. C., Chen, Y. J., Chen, C. J., et al. (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56(6), 782–789.PubMed

106.

Chang, Y. S., Kim, H. J., Chang, J., Ahn, C. M., Kim, S. K., & Kim, S. K. (2007). Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer, 57(3), 373–380.PubMed

107.

Bramwell, V. H., Doig, G. S., Tuck, A. B., Wilson, S. M., Tonkin, K. S., et al. (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clinical Cancer Research, 12(11), 3337–3343.PubMed

108.

Tuck, A. B., Elliott, B. E., Hota, C., Tremblay, E., & Chambers, A. F. (2000). Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). Journal of Cellular Biochemistry, 78(3), 465–475.PubMed

109.

Yoneda, T., Williams, P. J., & Niewolna, M. (1998). Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone, 23(5), 201–202.

110.

Oates, A. J., Barraclough, R., & Rudland, P. S. (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene, 13(1), 97–104.PubMed

111.

Chen, H., Ke, Y., Oates, A. J., Barraclough, R., & Rudland, P. S. (1997). Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene, 14(13), 1581–1588.PubMed

112.

Takahashi, F., Akutagawa, S., Fukumoto, H., Tsukiyama, S., Ohe, Y., Takahashi, K., et al. (2002). Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. International Journal of Cancer, 98(5), 707–712.

113.

Crawford, H. C., Matrisian, L. M., & Liaw, L. (1998). Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Research, 58(22), 5206–5215.PubMed

114.

Wu, Y., Denhardt, D. T., & Rittling, S. R. (2000). Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. British Journal of Cancer, 83(2), 156–163.PubMed

115.

Nemoto, H., Rittling, S. R., Yoshitake, H., Furuya, K., Amagasa, T., Tsuji, K., et al. (2001). Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. Journal of Bone and Mineral Research, 16(4), 652–659.PubMed

116.

Mukhopadhyay, R., & Price, J. E. (1999). Stable expression of Antisense osteopontin inhibits the growth of human breast cancer cells. Proceedings of the American Association for Cancer Research, 40(2), 448–449.

117.

Adwan, H., Bauerle, T. J., & Berger, M. R. (2003). Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy, 11(2), 109–120.

118.

Gardner, H. A., Berse, B., & Senger, D. R. (1994). Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9(8), 2321–2326.PubMed

119.

Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T., & Chambers, A. F. (1994). Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Research, 54(3), 832–837.PubMed

120.

Tanabe, K. K., Ellis, L. M., & Saya, H. (1993). Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet, 341(8847), 725–726.PubMed

121.

Stamenkovic, I., Aruffo, A., Amiot, M., & Seed, B. (1991). The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO Journal, 10(2), 343–348.PubMed

122.

Matsumura, Y., & Tarin, D. (1992). Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340(8827), 1053–1058.PubMed

123.

Tanabe, K. K., Stamenkovic, I., Cutler, M., & Takahashi, K. (1995). Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Annals of Surgery, 222(4), 493–501.PubMedCrossRef

124.

Takahashi, K., Stamenkovic, I., Cutler, M., Saya, H., & Tanabe, K. K. (1995). CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene, 11(11), 2223–2232.PubMed

125.

Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342–348.PubMed

126.

Lin, Y. H., & Yang-Yen, H. F. (2001). The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. Journal of Biological Chemistry, 276(49), 46024–46030.PubMed

127.

Hruska, K. A., Rolnick, F., Huskey, M., Alvarez, U., & Cheresh, D. (1995). Engagement of the osteoclast integrin alpha v beta 3 by osteopontin stimulates phosphatidylinositol 3-hydroxyl kinase activity. Endocrinology, 136(7), 2984–2992.PubMed

128.

Chellaiah, M., & Hruska, K. (1996). Osteopontin stimulates gelsolin-associated phosphoinositide levels and phosphatidylinositol triphosphate-hydroxyl kinase. Molecular Biology of the Cell, 7(5), 743–753.PubMed

129.

Urquidi, V., Sloan, D., Kawai, K., Agarwal, D., Woodman, A. C., Tarin, D., et al. (2002). Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clinical Cancer Research, 8(1), 61–74.PubMed

130.

Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., & Liotta, L. A. (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71(4), 1368–1383.PubMed

131.

Murphy, G., & Gavrilovic, J. (1999). Proteolysis and cell migration: creating a path? Current Opinion in Cell Biology, 11(5), 614–621.PubMed

132.

Philip, S., Bulbule, A., & Kundu, G. C. (2001). Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. Journal of Biological Chemistry, 276(48), 44926–44935.PubMed

133.

Tuck, A. B., Hota, C., & Chambers, A. F. (2001). Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Research and Treatment, 70(3), 197–204.PubMed

134.

Andreasen, P. A., Kjoller, L., Christensen, L., & Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer, 72(1), 1–22.

135.

Fisher, J. L., Field, C. L., Zhou, H., Harris, T. L., Henderson, M. A., & Choong, P. F. (2000). Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases—A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Research and Treatment, 61(1), 1–12.PubMed

136.

Philip, S., & Kundu, G. C. (2003). Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. Journal of Biological Chemistry, 278(16), 14487–14497.PubMed

137.

Das, R., Mahabeleshwar, G. H., & Kundu, G. C. (2003). Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. Journal of Biological Chemistry, 278(31), 28593–28606.PubMed

138.

Jain, S., Chakraborty, G., & Kundu, G. C. (2006). The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Research, 66(13), 6638–6648.PubMed

139.

Rangswami, H., Bulbule, A., & Kundu, G. C. (2004). Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. Journal of Biological Chemistry, 279(37), 38921–38935.

140.

Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134–1145.PubMed

141.

Mi, Z., Oliver, T., Guo, H., Gao, C., & Kuo, P. C. (2007). Thrombin-cleaved COOH(–) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Research, 67(9), 4088–4097.PubMed

142.

Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration: Diversity and escape mechanisms. Nature Reviews. Cancer, 3(5), 362–374.PubMed

143.

Tuck, A. B., Hota, C., Wilson, S. M., & Chambers, A. F. (2003). Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways. Oncogene, 22(8), 1198–1205.PubMed

144.

Hayashi, C., Rittling, S., Hayata, T., Amagasa, T., Denhardt, D., Ezura, Y., et al. (2007). Serum osteopontin, an enhancer of tumor metastasis to bone, promotes B16 melanoma cell migration. Journal of Cellular Biochemistry, 101(4), 979–986.PubMed

145.

Denhardt, D. T., & Chambers, A. F. (1994). Overcoming obstacles to metastasis–defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. Journal of Cellular Biochemistry, 56(1), 48–51.PubMed

146.

Gao, C., Guo, H., Wei, J., & Kuo, P. C. (2003). Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochemical and Biophysical Research Communications, 309(1), 120–125.PubMed

147.

Guo, H., Cai, C. Q., Schroeder, R. A., & Kuo, P. C. (2001). Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. Journal of Immunology, 166(2), 1079–1086.

148.

Gao, C., Guo, H., Mi, Z., Wai, P. Y., & Kuo, P. C. (2005). Transcriptional regulatory functions of heterogeneous nuclear ribonucleoprotein-U and -A/B in endotoxin-mediated macrophage expression of osteopontin. Journal of Immunology, 175(1), 523–530.

149.

Wai, P. Y., Guo, L., Gao, C., Mi, Z., Guo, H., & Kuo, P. C. (2006). Osteopontin inhibits macrophage nitric oxide synthesis to enhance tumor proliferation. Surgery, 40(2), 132–140.

150.

151.

Nagasaki, T., Ishimura, E., Koyama, H., Shioi, A., Jono, S., Inaba, M., et al. (1999). Alphav integrin regulates TNF-alpha-induced nitric oxide synthesis in rat mesangial cells—Possible role of osteopontin. Nephrology Dialysis Transplantation, 14(8), 1861–1866.

152.

Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29(6), 15–18.PubMed

153.

Hanrahan, V., Currie, M. J., Gunningham, S. P., Morrin, H. R., Scott, P. A., Robinson, B. A., et al. (2003). The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma–carcinoma sequence during colorectal cancer progression. Journal of Pathology, 200(2), 183–194.PubMed

154.

Nakamura, Y., Yasuoka, H., Tsujimoto, M., Yang, Q., Imabun, S., Nakahara, M., et al. (2003). Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clinical Cancer Research, 9(2), 716–721.PubMed

155.

Hirama, M., Takahashi, F., Takahashi, K., Akutagawa, S., Shimizu, K., Soma, S., et al. (2003). Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Letters, 198(1), 107–117.PubMed

156.

Leali, D., Dell, , Era, P., Stabile, H., Sennino, B., Chambers, A. F., Naldini, A., et al. (2003). Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. Journal of Immunology, 171(2), 1085–1093.

157.

Khan, S. A., Lopez-Chua, C. A., Zhang, J., Fisher, L. W., Sorensen, E. S., & Denhardt, D. T. (2002). Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. Journal of Cellular Biochemistry, 85(4), 728–736.PubMed

158.

Malyankar, U. M., Hanson, R., Schwartz, S. M., Ridall, A. L., & Giachelli, C. M. (1999). Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells. Experimental Cell Research, 250(2), 535–547.PubMed

159.

Zhang, Q., Wrana, J. L., & Sodek, J. (1992). Characterization of the promoter region of the porcine opn (osteopontin, secreted phosphoprotein 1) gene. Identification of positive and negative regulatory elements and a ‘silent’ second promoter. European Journal of Biochemistry, 207(2), 649–659.PubMed

160.

Eferl, R., & Wagner, E. F. (2003). AP-1: A double-edged sword in tumorigenesis. Nature Reviews. Cancer, 3(11), 859–868.PubMed

161.

Deng, T., & Karin, M. (1993). JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes & Development, 7(3), 479–490.

162.

Chiu, R., Angel, P., & Karin, M. (1989). Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell, 59(6), 979–986.PubMed

163.

Wang, Z. Q., Grigoriadis, A. E., Mohle-Steinlein, U., & Wagner, E. F. (1991). A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras. EMBO Journal, 10(9), 2437–2450.PubMed

164.

Grigoriadis, A. E., Schellander, K., Wang, Z. Q., & Wagner, E. F. (1993). Osteoblasts are target cells for transformation in c-fos transgenic mice. Journal of Cell Biology, 122(3), 685–701.PubMed

165.

Young, M. R., Li, J. J., Rincon, M., Flavell, R. A., Sathyanarayana, B. K., Hunziker, R., et al. (1999). Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proceedings of the National Academy of Sciences of the United States of America, 96(17), 9827–9832.PubMed

166.

Jochum, W., David, J. P., Elliott, C., Wutz, A., Plenk Jr, H., Matsuo, K., et al. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nature Medicine, 6(9), 980–984.PubMed

167.

Renault, M. A., Jalvy, S., Belloc, I., Pasquet, S., Sena, S., Olive, M., et al. (2003). AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circulation Research, 93(7), 674–681.PubMed

168.

Kim, H. J., Lee, M. H., Kim, H. J., Shin, H. I., Choi, J. Y., & Ryoo, H. M. (2002). Okadaic acid stimulates osteopontin expression through de novo induction of AP-1. Journal of Cellular Biochemistry, 87(1), 93–102.PubMed

169.

170.

Wang, D., Yamamoto, S., Hijiya, N., Benveniste, E. N., & Gladson, C. L. (2000). Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA–protein interactions. Oncogene, 19(50), 5801–5809.PubMed

171.

Kiermaier, A., Gawn, J. M., Desbarats, L., Saffrich, R., Ansorge, W., Farrell, P. J., et al. (1999). DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene, 18(51), 7200–7211.PubMed

172.

Sirito, M., Lin, Q., Deng, J. M., Behringer, R. R., & Sawadogo, M. (1998). Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proceedings of the National Academy of Sciences of the United States of America, 95(7), 3758–3763.PubMed

173.

Atchley, W. R., & Fitch, W. M. (1997). A natural classification of the basic helix–loop–helix class of transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 94(10), 5172–5176.PubMed

174.

Jaiswal, A. S., & Narayan, S. (2001). Upstream stimulating factor-1 (USF1) and USF2 bind to and activate the promoter of the adenomatous polyposis coli (APC) tumor suppressor gene. Journal of Cellular Biochemistry, 81(2), 262–277.PubMed

175.

Reisman, D., & Rotter, V. (1993). The helix–loop–helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Research, 21(2), 345–350.PubMed

176.

Bidder, M., Shao, J. S., Charlton-Kachigian, N., Loewy, A. P., Semenkovich, C. F., & Towler, D. A. (2002). Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. Journal of Biological Chemistry, 277(46), 44485–44496.PubMed

177.

Tezuka, K., Denhardt, D. T., Rodan, G. A., & Harada, S. (1996). Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. Journal of Biological Chemistry, 271(37), 22713–22717.PubMed

178.

Blobel, G. A., & Hanafusa, H. (1991). The v-src inducible gene 9E3/pCEF4 is regulated by both its promoter upstream sequence and its 3′ untranslated region. Proceedings of the National Academy of Sciences of the United States of America, 88(4), 1162–1166.PubMed

179.

Schonthal, A., Herrlich, P., Rahmsdorf, H. J., & Ponta, H. (1988). Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. Cell, 54(3), 325–334.PubMed

180.

Birchenall-Roberts, M. C., Ruscetti, F. W., Kasper, J., Lee, H. D., Friedman, R., Geiser, A., et al. (1990). Molecular and Cellular Biology, 10(9), 4978–4983.PubMed

181.

Fujii, M., Shalloway, D., & Verma, I. M. (1989). Gene regulation by tyrosine kinases: Src protein activates various promoters, including c-fos. Molecular and Cellular Biology, 9(6), 2493–2499.PubMed

182.

Apel, I., Yu, C. L., Wang, T., Dobry, C., Van Antwerp, M. E., Jove, R., et al. (1992). Regulation of the junB gene by v-src. Molecular and Cellular Biology, 12(8), 3356–3364.PubMed

183.

Sato, H., Kita, M., & Seiki, M. (1993). v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. Journal of Biological Chemistry, 268(31), 23460–23468.PubMed

184.

Lund, A. H., & van Lohuizen, M. (2002). RUNX: a trilogy of cancer genes. Cancer Cell, 1(3), 213–215.PubMed

185.

Coffman, J. A. (2003). Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biology International, 27(4), 315–324.PubMed

186.

Ito, Y., & Miyazono, K. (2003). RUNX transcription factors as key targets of TGF-beta superfamily signaling. Current Opinion in Genetics & Development, 13(1), 43–47.

187.

Li, Q. L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X. Z., et al. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109(1), 113–124.PubMed

188.

Speck, N. A., & Gilliland, D. G. (2002). Core-binding factors in haematopoiesis and leukaemia. Nature Reviews. Cancer, 2(7), 502–513.PubMed

189.

Inman, C. K., & Shore, P. (2003). The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. Journal of Biological Chemistry, 278(49), 48684–48689.PubMed

190.

Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., et al. (1997). Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89(5), 765–771.PubMed

191.

Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89(5), 755–764.PubMed

192.

Sato, M., Morii, E., Komori, T., Kawahata, H., Sugimoto, M., Terai, K., et al. (1998). Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene, 17(12), 1517–1525.PubMed

193.

Barnes, G. L., Javed, A., Waller, S. M., Kamal, M. H., Hebert, K. E., Hassan, M. Q., et al. (2003). Cancer Research, 63(10), 2631–2637.PubMed

194.

Wai, P. Y., Mi, Z., Gao, C., Guo, H., Marroquin, C., & Kuo, P. C. (2006). Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. Journal of Biological Chemistry, 281(28), 18973–18982.PubMed

195.

Lee, K. S., Kim, H. J., Li, Q. L., Chi, X. Z., Ueta, C., Komori, T., et al. (2000). Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Molecular and Cellular Biology, 20(23), 8783–92.PubMed

196.

Hanai, J., Chen, L. F., Kanno, T., Ohtani-Fujita, N., Kim, W. Y., Guo, W. H., et al. (1999). Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. Journal of Biological Chemistry, 274(44), 31577–31582.PubMed

197.

Shi, X., Bai, S., Li, L., & Cao, X. (2001). Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. Journal of Biological Chemistry, 276(1), 850–855.PubMed

198.

Roberts, A. B., & Wakefield, L. M. (2003). The two faces of transforming growth factor beta in carcinogenesis.Proceedings of the National Academy of Sciences of the United States of America, 100(15), 8621–8623.PubMed

199.

Medrano, E. E. (2003). Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene, 22(20), 3123–3129.PubMed

200.

Bello-DeOcampo, D., & Tindall, D. J. (2003). TGF-betal/Smad signaling in prostate cancer. Current Drugs Targets, 4(3), 197–207.

201.

Guise, T. A., & Chirgwin, J. M. (2003). Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinica Ortopedica, 415(Suppl), S32–S38.

202.

Kim, S. J., & Letterio, J. (2003). Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia, 17(9), 1731–1737.PubMed

203.

Noda, M., Yoon, K., Prince, C. W., Butler, W. T., & Rodan, G. A. (1988). Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. Journal of Biological Chemistry, 263(27), 13916–13921.PubMed

204.

Wrana, J. L., Kubota, T., Zhang, Q., Overall, C. M., Aubin, J. E., Butler, W. T., et al. (1991). Regulation of transformation-sensitive secreted phosphoprotein (SPPI/osteopontin) expression by transforming growth factor-beta. Comparisons with expression of SPARC (secreted acidic cysteine-rich protein). Biochemical Journal, 273(3), 523–531.PubMed

205.

Cheifetz, S., Li, I. W., McCulloch, C. A., Sampath, K., & Sodek, J. (1996). Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-beta 1 on bone formation in vitro. Connective Tissue Research, 35(1–4), 71–78.PubMed

206.

Hullinger, T. G., Pa, N. Q., Viswanatha, N. H. L., & Somerman, M. J. (2001). TGFbeta and BMP-2 activation of the OPN promoter: Roles of smad- and hox-binding elements. Experimental Cell Research, 262(1), 69–74.PubMed

207.

Cui, J., Zhou, X., Liu, Y., Tang, Z., & Romeih, M. (2003). Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. Journal of Gastroenterology and Hepatology, 18(3), 280–287.PubMed

208.

Bright-Thomas, R. M., & Hargest, R. (2003). APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer. European Journal of Surgical Oncology, 29(2), 107–117.PubMed

209.

El-Tanani, M., Barraclough, R., Wilkinson, M. C., & Rudland, P. S. (2001). Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Research, 61(14), 5619–5629.PubMed

210.

Denhardt, D. T., Mistretta, D., Chambers, A. F., Krishna, S., Porter, J. F., Raghuram, S., et al. (2003). Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter. Clinical & Experimental Metastasis, 20(1), 77–84.

211.

Bos, J. L. (1989). Ras oncogenes in human cancer: A review. Cancer Research, 49(17), 4682–4689.PubMed

212.

Chambers, A. F., Behrend, E. I., Wilson, S. M., & Denhardt, D. T. (1992). Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Research, 12(1), 43–47.PubMed

213.

Guo, X., Zhang, Y. P., Mitchell, D. A., Denhardt, D. T., & Chambers, A. F. (1995). Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Molecular and Cellular Biology, 15(1), 476–487.PubMed

214.

Morimoto, I., Sasaki, Y., Ishida, S., Imai, K., & Tokino, T. (2002). Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer, 33(3), 270–278.PubMed

215.

Safe, S., & Abdelrahim, M. (2005). Sp transcription factor family and its role in cancer. European Journal of Cancer, 41(16), 2438–24348.PubMed

216.

Takami, Y., Russell, M. B., Gao, C., Mi, Z., Guo, H., Mantyh, C. R., et al. (2007). Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells. Surgery, 142(2), 163–169.PubMed

217.

el-Deiry, W. S. (1998). Seminars in Cancer Biology, 8(5), 345–357.PubMed

218.

Tokino, T., & Nakamura, Y. (2000). The role of p53-target genes in human cancer. Critical Reviews in Oncology/Hematology, 33(1), 1–6.PubMed

219.

Vogelstein, B., Lane, D., & Levine, A. J. (2000). Surfing the p53 network. Nature, 408(6810), 307–310.PubMed

220.

Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., & Chen, X. (1999). p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene, 18(54), 7740–7747.PubMed

221.

Craig, A. M., Bowde, N. G. T., Chambers, A. F., Spearman, M. A., Greenberg, A. H., Wright, J. A., et al. (1990). Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. International Journal of Cancer, 46(1), 133–137.

222.

Chang, P. L., Tucker, M. A., Hicks, P. H., & Prince, C. W. (2002). Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. International Journal of Biochemistry & Cell Biology, 34(9), 1142–1151.

223.

Manji, S. S., Ng, K. W., Martin, T. J., & Zhou, H. (1998). Transcriptional and posttranscriptional regulation of osteopontin gene expression in preosteoblasts by retinoic acid. Journal of Cellular Physiology, 176(1), 1–9.PubMed

224.

Asaumi, S., Takemoto, M., Yokote, K., Ridall, A. L., Butler, W. T., Fujimoto, M., et al. (2003). Identification and characterization of high glucose and glucosamine responsive element in the rat osteopontin promoter. Journal of Diabetes and Its Complications, 17(1), 34–38.PubMed

225.

Noda, M., Vogel, R. L., Craig, A. M., Prahl, J., DeLuca, H. F., & Denhardt, D. T. (1990). Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proceedings of the National Academy of Sciences of the United States of America, 87(24), 9995–9999.PubMed

Titel: Osteopontin: regulation in tumor metastasis
verfasst von: Philip Y. Wai
Paul C. Kuo
Publikationsdatum: 01.03.2008
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2008
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-007-9104-9

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

ASS schützt nicht vor Brustkrebsrezidiven

02.05.2024 Mammakarzinom Nachrichten

Nützt nichts und ist vielleicht sogar schädlich: In einer Phase-3-Studie konnten täglich 300 mg ASS keine Brustkrebsrezidive bei Frauen vermeiden, die ein hohes Risiko für eine Tumorrückkehr aufwiesen. Tendenziell traten unter ASS sogar häufiger Rezidive auf als unter Placebo.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Bildnachweise

Frau nutzt Gehhilfe /© Photographee.eu / Fotolia (Symbolbild mit Fotomodellen), Darstellung der Dosisverteilung bei Bestrahlung eines Prostatakarzinoms/© Degener, S et al. / all rights reserved Springer Medizin Verlag GmbH, Frau mit Tablette und Wasserglas in Händen/© fizkes / stock.adobe.com (Symbolbild mit Fotomodell), Ärztin und künstliche Intelligenz sehen sich Befunde an/© Alexander Limbach / Zoonar/picture alliance (Symbolbild mit Fotomodell)

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Osteopontin: regulation in tumor metastasis

Abstract

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Tumor microenvironment, a dangerous society leading to cancer metastasis. From mechanisms to therapy and prevention

Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment

The Met tyrosine kinase receptor in development and cancer

Bio

A “class action” against the microenvironment: do cancer cells cooperate in metastasis?

Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells

Neu im Fachgebiet Onkologie

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

ASS schützt nicht vor Brustkrebsrezidiven

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Update Onkologie